Clinical Trial Update: A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated the safety of adjuvant exemestane after prior tamoxifen in postmenopausal women with estrogen receptor-positive primary breast cancer.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 4 | Status: COMPLETED